Valuation : Theraclion

Market Cap 4.72Cr 5.49Cr 4.41Cr 4.04Cr 7.62Cr 524.66Cr 7.64Cr 52Cr 20Cr 264.42Cr 21Cr 20Cr 875.14Cr P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 5.5Cr 6.41Cr 5.15Cr 4.72Cr 8.88Cr 612.02Cr 8.91Cr 61Cr 24Cr 308.45Cr 24Cr 24Cr 1.02TCr EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
39.01%
Yield 2024 *
-
Yield 2025 -
1 day-2.95%
1 week-4.86%
Current month+7.75%
1 month+5.56%
3 months+0.97%
6 months+0.64%
Current year+3.99%
1 week 0.62
Extreme 0.618
0.68
1 month 0.54
Extreme 0.535
0.71
Current year 0.4
Extreme 0.402
0.93
1 year 0.4
Extreme 0.402
1.25
3 years 0.14
Extreme 0.1416
1.25
5 years 0.14
Extreme 0.1416
2.22
10 years 0.14
Extreme 0.1416
6.48
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 22/06/2021
Director/Board Member - 28/01/2022
Director/Board Member - 29/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.95%-4.86%-21.75%+0.97% 5.49Cr
+0.10%+1.16%+30.05%+16.44% 23TCr
+0.36%+0.28%+5.61%-17.20% 15TCr
-0.44%-1.61%-21.80%+22.21% 13TCr
-1.86%-4.13%-55.29%-12.01% 6.98TCr
+0.17%+1.20%+12.37%+19.56% 5.23TCr
0.00%-1.38%-16.80%-14.19% 5.09TCr
+1.43%+0.99%+32.99%+31.62% 4.38TCr
+2.06%+4.76%+43.90%+50.64% 4.07TCr
+0.79%+3.87%-15.85%+46.58% 3.4TCr
Average -0.04%-0.12%-0.66%+14.46% 8.08TCr
Weighted average by Cap. +0.09%-0.04%+4.53%+10.70%

Financials

2024 2025
Net sales 8L 10L 8L 7L 13.41L 9.24Cr 13.45L 92.04L 35.98L 4.66Cr 36.31L 35.53L 15Cr 7L 8L 6L 6L 10.53L 7.25Cr 10.56L 72.28L 28.26L 3.66Cr 28.52L 27.9L 12Cr
Net income -57.57L -67.07L -53.9L -49.35L -92.97L -64Cr -93.24L -6.38Cr -2.49Cr -32Cr -2.52Cr -2.46Cr -106.84Cr -56.9L -66.29L -53.27L -48.78L -91.89L -63Cr -92.15L -6.31Cr -2.47Cr -32Cr -2.49Cr -2.43Cr -105.6Cr
Net Debt 34.11L 39.73L 31.93L 29.24L 55.08L 38Cr 55.24L 3.78Cr 1.48Cr 19Cr 1.49Cr 1.46Cr 63Cr 78.52L 91.47L 73.51L 67.31L 1.27Cr 87Cr 1.27Cr 8.7Cr 3.4Cr 44Cr 3.43Cr 3.36Cr 145.72Cr
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change Volume
27/26/27 0.6260 -2.95% 43,228
26/26/26 €0.6450 +1.74% 47,209
25/26/25 €0.6340 -0.94% 50,744
24/26/24 €0.6400 -1.08% 1,13,610
21/26/21 €0.6470 -1.67% 23,754

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALTHE Stock